Teleflex (TFX)
(Delayed Data from NYSE)
$206.71 USD
-4.46 (-2.11%)
Updated Apr 25, 2024 04:00 PM ET
After-Market: $206.94 +0.23 (0.11%) 7:58 PM ET
4-Sell of 5 4
B Value D Growth B Momentum C VGM
Teleflex (TFX) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$264.50 | $285.00 | $240.00 | 27.96% |
Price Target
Based on short-term price targets offered by 12 analysts, the average price target for Teleflex comes to $264.50. The forecasts range from a low of $240.00 to a high of $285.00. The average price target represents an increase of 27.96% from the last closing price of $206.71.
Analyst Price Targets (12)
Broker Rating
Teleflex currently has an average brokerage recommendation (ABR) of 2.36 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 14 brokerage firms. The current ABR compares to an ABR of 2.36 a month ago based on 14 recommendations.
Of the 14 recommendations deriving the current ABR, three are Strong Buy and three are Buy. Strong Buy and Buy respectively account for 21.43% and 21.43% of all recommendations. A month ago, Strong Buy made up 21.43%, while Buy represented 21.43%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 3 | 3 | 3 | 3 | 3 |
Buy | 3 | 3 | 3 | 3 | 3 |
Hold | 8 | 8 | 8 | 8 | 8 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 2.36 | 2.36 | 2.36 | 2.36 | 2.36 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
2/23/2024 | JMP Securities | David L Turkaly | Strong Buy | Strong Buy |
2/23/2024 | Truist Securities | Richard Newitter | Hold | Hold |
2/23/2024 | Mizuho SecuritiesUSA | Anthony Petrone | Hold | Hold |
1/17/2024 | C.L. King & Associates | Kristen M Stewart | Moderate Buy | Moderate Buy |
1/17/2024 | Needham & Company | Michael Matson | Hold | Hold |
1/16/2024 | Stephens | George Sellers | Strong Buy | Strong Buy |
1/16/2024 | Piper Sandler | Matthew O'Brien | Hold | Hold |
12/20/2023 | Raymond James | Jayson T Bedford | Moderate Buy | Moderate Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.36 |
ABR (Last week) | 2.36 |
# of Recs in ABR | 14 |
Average Target Price | $264.50 |
LT Growth Rate | 7.60% |
Industry | Medical - Instruments |
Industry Rank by ABR | 86 of 252 |
Current Quarter EPS Est: | 3.07 |